Takeda Pharmaceutical Company is a Japanese multinational pharmaceutical company headquartered in Tokyo. Founded in 1781, it is among the largest pharmaceutical companies globally and is listed in both Tokyo and New York.
AstraZeneca will report pivotal first-half data on sonesitatug vedotin in Claudin18.2 gastric cancer. The phase 3 Clarity-Gastric01 study is enrolling patients with ≥25% expression.
Artificial intelligence is being adopted across clinical development and could shorten drug development timelines by roughly 18 months while lowering R&D spending by about 5%. Data provenance and consent frameworks remain key issues as pharma companies expand AI use.
Market analysis reports project substantial growth through 2033 across sarcopenia treatments, oncology injection drugs, and ASO-based therapies. Major pharmaceutical companies including Pfizer, Merck, Roche, Novartis, and Amgen feature prominently across all three therapeutic areas. The reports cover market segmentation, geographic analysis, and competitive landscapes for each sector.
The multiple myeloma treatment landscape is rapidly expanding with over 75 companies developing 80+ pipeline therapies, while clinicians navigate evolving questions about transplant timing, quadruplet regimens, and minimal residual disease testing in newly diagnosed patients.
The FDA announced major policy changes including requiring only one study for drug approvals instead of two, and offering performance bonuses to reviewers who complete work ahead of schedule while maintaining thoroughness.
The FDA accepted Takeda's new drug application for oveporexton, an investigational orexin 2 receptor agonist for narcolepsy type 1, and granted priority review with a PDUFA action date in Q3 2026.
Over 25 companies are developing 30+ therapies for celiac disease, with recent positive trial results and FDA Fast Track designation. A new blood test using T-cell receptor sequencing may enable noninvasive diagnosis and monitoring.
Protagonist Therapeutics reported fourth quarter and full year 2025 financial results, with two NDAs submitted and multiple Phase 3 trials advancing. The company holds $646 million in cash and expects regulatory decisions in 2026.
The FDA has accepted the New Drug Application for rusfertide, a first-in-class hepcidin mimetic peptide for polycythemia vera, and granted Priority Review with a PDUFA goal date in the third quarter of 2026.
Industry leaders highlight advances in AI-enabled trial monitoring, real-world data interoperability, and protocol-driven eSource systems, while emphasizing the need for community engagement in diversity efforts and addressing operational risks in rare disease trials.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07501793 |
Demographic Characteristics of TAK-003 Dengue Vaccine Recipients in Vietnam |
ACTIVE_NOT_RECRUITING | |
| NCT07494058 |
A Study of Home vs Hospital Treatment in People With Fabry, Gaucher or Hunter Conditions in Mexico |
ACTIVE_NOT_RECRUITING | |
| NCT07445087 |
A Study of Takhzyro in Teenagers and Adults With Hereditary Angioedema (HAE) in South Korea |
NOT_YET_RECRUITING | |
| NCT07436728 |
A Study of TAK-505 in Adults With Solid Tumors |
RECRUITING | PHASE1/PHASE2 |
| NCT07429942 |
A Study to Learn More About the Treatment of People With Congenital Thrombotic Thrombocytopenic Purpura (cTTP) Who Received Recombinant ADAMTS13 (rADAMTS13) as Part of the Early Access Program |
NOT_YET_RECRUITING | |
| NCT07422480 |
A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions |
RECRUITING | PHASE3 |
| NCT07404644 |
An Observational Study of Vonicog Alfa (rVWF) in Pediatric Participants With Von Willebrand Disease (vWD) |
RECRUITING | |
| NCT07403968 |
A Study of Zasocitinib (TAK-279) in Adults With Active Crohn's Disease |
NOT_YET_RECRUITING | PHASE2 |
| NCT07392450 |
A Study of TAK-755 in Adults With Acute Ischemic Stroke |
RECRUITING | PHASE2 |
| NCT07363720 |
A Trial of TAK-861 for the Treatment of Narcolepsy With Cataplexy |
RECRUITING | PHASE3 |
